Prevalence of HIV-1 Subtypes and Drug Resistance-Associated Mutations in HIV-1-Positive Treatment-Naive Pregnant Women in Pointe Noire, Republic of the Congo (Kento-Mwana Project)

Bianca Bruzzone, Francesco Saladini, Laura Sticchi, Franc A. Mayinda Mboungou, Renata Barresi, Patrizia Caligiuri, Anna Calzi, Maurizio Zazzi, Giancarlo Icardi, Claudio Viscoli, Francesca Bisio

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The Kento-Mwana project was carried out in Pointe Noire, Republic of the Congo, to prevent mother-to-child HIV-1 transmission. To determine the prevalence of different subtypes and transmitted drug resistance-associated mutations, 95 plasma samples were collected at baseline from HIV-1-positive naive pregnant women enrolled in the project during the years 2005-2008. Full protease and partial reverse transcriptase sequencing was performed and 68/95 (71.6%) samples were successfully sequenced. Major mutations to nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors were detected in 4/68 (5.9%), 3/68 (4.4%), and 2/68 (2.9%) samples, respectively. Phylogenetic analysis of HIV-1 isolates showed a high prevalence of unique recombinant forms (24/68, 35%), followed by CRF45-cpx (7/68, 10.3%) and subsubtype A3 and subtype G (6/68 each, 8.8%). Although the prevalence of transmitted drug resistance mutations appears to be currently limited, baseline HIV-1 genotyping is highly advisable in conjunction with antiretroviral therapy scale-up in resource-limited settings to optimize treatment and prevent perinatal transmission.

Original languageEnglish
Pages (from-to)837-840
Number of pages4
JournalAIDS Research and Human Retroviruses
Volume31
Issue number8
DOIs
Publication statusPublished - Aug 1 2015

Fingerprint

Congo
Drug Resistance
HIV-1
Pregnant Women
Mutation
Reverse Transcriptase Inhibitors
RNA-Directed DNA Polymerase
Therapeutics
Protease Inhibitors
Nucleosides
Peptide Hydrolases
Mothers

ASJC Scopus subject areas

  • Immunology
  • Virology
  • Infectious Diseases

Cite this

Prevalence of HIV-1 Subtypes and Drug Resistance-Associated Mutations in HIV-1-Positive Treatment-Naive Pregnant Women in Pointe Noire, Republic of the Congo (Kento-Mwana Project). / Bruzzone, Bianca; Saladini, Francesco; Sticchi, Laura; Mayinda Mboungou, Franc A.; Barresi, Renata; Caligiuri, Patrizia; Calzi, Anna; Zazzi, Maurizio; Icardi, Giancarlo; Viscoli, Claudio; Bisio, Francesca.

In: AIDS Research and Human Retroviruses, Vol. 31, No. 8, 01.08.2015, p. 837-840.

Research output: Contribution to journalArticle

Bruzzone, Bianca ; Saladini, Francesco ; Sticchi, Laura ; Mayinda Mboungou, Franc A. ; Barresi, Renata ; Caligiuri, Patrizia ; Calzi, Anna ; Zazzi, Maurizio ; Icardi, Giancarlo ; Viscoli, Claudio ; Bisio, Francesca. / Prevalence of HIV-1 Subtypes and Drug Resistance-Associated Mutations in HIV-1-Positive Treatment-Naive Pregnant Women in Pointe Noire, Republic of the Congo (Kento-Mwana Project). In: AIDS Research and Human Retroviruses. 2015 ; Vol. 31, No. 8. pp. 837-840.
@article{ab99701a1eb742b887c239633adb9d2e,
title = "Prevalence of HIV-1 Subtypes and Drug Resistance-Associated Mutations in HIV-1-Positive Treatment-Naive Pregnant Women in Pointe Noire, Republic of the Congo (Kento-Mwana Project)",
abstract = "The Kento-Mwana project was carried out in Pointe Noire, Republic of the Congo, to prevent mother-to-child HIV-1 transmission. To determine the prevalence of different subtypes and transmitted drug resistance-associated mutations, 95 plasma samples were collected at baseline from HIV-1-positive naive pregnant women enrolled in the project during the years 2005-2008. Full protease and partial reverse transcriptase sequencing was performed and 68/95 (71.6{\%}) samples were successfully sequenced. Major mutations to nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors were detected in 4/68 (5.9{\%}), 3/68 (4.4{\%}), and 2/68 (2.9{\%}) samples, respectively. Phylogenetic analysis of HIV-1 isolates showed a high prevalence of unique recombinant forms (24/68, 35{\%}), followed by CRF45-cpx (7/68, 10.3{\%}) and subsubtype A3 and subtype G (6/68 each, 8.8{\%}). Although the prevalence of transmitted drug resistance mutations appears to be currently limited, baseline HIV-1 genotyping is highly advisable in conjunction with antiretroviral therapy scale-up in resource-limited settings to optimize treatment and prevent perinatal transmission.",
author = "Bianca Bruzzone and Francesco Saladini and Laura Sticchi and {Mayinda Mboungou}, {Franc A.} and Renata Barresi and Patrizia Caligiuri and Anna Calzi and Maurizio Zazzi and Giancarlo Icardi and Claudio Viscoli and Francesca Bisio",
year = "2015",
month = "8",
day = "1",
doi = "10.1089/aid.2015.0105",
language = "English",
volume = "31",
pages = "837--840",
journal = "AIDS Research and Human Retroviruses",
issn = "0889-2229",
publisher = "Mary Ann Liebert Inc.",
number = "8",

}

TY - JOUR

T1 - Prevalence of HIV-1 Subtypes and Drug Resistance-Associated Mutations in HIV-1-Positive Treatment-Naive Pregnant Women in Pointe Noire, Republic of the Congo (Kento-Mwana Project)

AU - Bruzzone, Bianca

AU - Saladini, Francesco

AU - Sticchi, Laura

AU - Mayinda Mboungou, Franc A.

AU - Barresi, Renata

AU - Caligiuri, Patrizia

AU - Calzi, Anna

AU - Zazzi, Maurizio

AU - Icardi, Giancarlo

AU - Viscoli, Claudio

AU - Bisio, Francesca

PY - 2015/8/1

Y1 - 2015/8/1

N2 - The Kento-Mwana project was carried out in Pointe Noire, Republic of the Congo, to prevent mother-to-child HIV-1 transmission. To determine the prevalence of different subtypes and transmitted drug resistance-associated mutations, 95 plasma samples were collected at baseline from HIV-1-positive naive pregnant women enrolled in the project during the years 2005-2008. Full protease and partial reverse transcriptase sequencing was performed and 68/95 (71.6%) samples were successfully sequenced. Major mutations to nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors were detected in 4/68 (5.9%), 3/68 (4.4%), and 2/68 (2.9%) samples, respectively. Phylogenetic analysis of HIV-1 isolates showed a high prevalence of unique recombinant forms (24/68, 35%), followed by CRF45-cpx (7/68, 10.3%) and subsubtype A3 and subtype G (6/68 each, 8.8%). Although the prevalence of transmitted drug resistance mutations appears to be currently limited, baseline HIV-1 genotyping is highly advisable in conjunction with antiretroviral therapy scale-up in resource-limited settings to optimize treatment and prevent perinatal transmission.

AB - The Kento-Mwana project was carried out in Pointe Noire, Republic of the Congo, to prevent mother-to-child HIV-1 transmission. To determine the prevalence of different subtypes and transmitted drug resistance-associated mutations, 95 plasma samples were collected at baseline from HIV-1-positive naive pregnant women enrolled in the project during the years 2005-2008. Full protease and partial reverse transcriptase sequencing was performed and 68/95 (71.6%) samples were successfully sequenced. Major mutations to nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors were detected in 4/68 (5.9%), 3/68 (4.4%), and 2/68 (2.9%) samples, respectively. Phylogenetic analysis of HIV-1 isolates showed a high prevalence of unique recombinant forms (24/68, 35%), followed by CRF45-cpx (7/68, 10.3%) and subsubtype A3 and subtype G (6/68 each, 8.8%). Although the prevalence of transmitted drug resistance mutations appears to be currently limited, baseline HIV-1 genotyping is highly advisable in conjunction with antiretroviral therapy scale-up in resource-limited settings to optimize treatment and prevent perinatal transmission.

UR - http://www.scopus.com/inward/record.url?scp=84938896206&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938896206&partnerID=8YFLogxK

U2 - 10.1089/aid.2015.0105

DO - 10.1089/aid.2015.0105

M3 - Article

C2 - 25970260

AN - SCOPUS:84938896206

VL - 31

SP - 837

EP - 840

JO - AIDS Research and Human Retroviruses

JF - AIDS Research and Human Retroviruses

SN - 0889-2229

IS - 8

ER -